WilmerHale Represents Trevi Therapeutics in Securing $50M in Series C Financing

WilmerHale Represents Trevi Therapeutics in Securing $50M in Series C Financing

Firm News

Related Solutions

We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Helping clients launch their businesses and transform their innovative ideas into successful companies.

Trevi Therapeutics, Inc. announced that they have completed a Series C financing of $50.5 million led by New Enterprise Associates. The company plans to use the proceeds from the financing to advance the development of Nalbuphine® ER, a drug with a dual agonist/antagonist mechanism of action uniquely suited to treating itch associated in various dermatologic, metabolic, hematologic, and neuropathic conditions.

The WilmerHale deal team counseling Trevi Therapeutics was led by Stuart Falber and included Sam Rothberg and Cara Fonseca.

Read Trevi Therapeutics' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel